Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLSD Stock Forecast 2026-2027
$1.10
Current Price
$5.76M
Market Cap
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to CLSD Price Targets
+8,081.8%
To High Target of $90.00
+5,354.5%
To Median Target of $60.00
+2,627.3%
To Low Target of $30.00
CLSD Price Momentum
+54.9%
1 Week Change
+5.8%
1 Month Change
-92.2%
1 Year Change
+57.1%
Year-to-Date Change
-93.6%
From 52W High of $17.10
+254.8%
From 52W Low of $0.31
📊 TOP ANALYST CALLS
Did CLSD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Clearside is one of their latest high-conviction picks.
Latest CLSD Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, CLSD has a neutral consensus with a median price target of $60.00 (ranging from $30.00 to $90.00). The overall analyst rating is Buy (6.0/10). Currently trading at $1.10, the median forecast implies a 5,354.5% upside. This outlook is supported by 0 Buy, 6 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLSD Analyst Ratings
0
Buy
6
Hold
0
Sell
CLSD Price Target Range
Low
$30.00
Average
$60.00
High
$90.00
Current: $1.10
Latest CLSD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLSD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 18, 2025 | Needham | Serge Belanger | Hold | Reiterates | $N/A |
| Jul 18, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Downgrade | $5.00 |
| Jul 18, 2025 | Chardan Capital | Daniil Gataulin | Neutral | Downgrade | $N/A |
| Jul 17, 2025 | Needham | Serge Belanger | Hold | Downgrade | $3.00 |
| May 23, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $5.00 |
| May 16, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $5.00 |
| May 15, 2025 | Needham | Serge Belanger | Buy | Maintains | $3.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $4.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Mar 28, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $5.00 |
| Mar 28, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $6.00 |
| Mar 28, 2025 | Needham | Serge Belanger | Buy | Maintains | $4.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Mar 6, 2025 | Needham | Serge Belanger | Buy | Reiterates | $6.00 |
| Nov 15, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $6.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Nov 13, 2024 | Needham | Serge Belanger | Buy | Reiterates | $6.00 |
| Oct 14, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $6.00 |
| Oct 10, 2024 | Needham | Serge Belanger | Buy | Maintains | $6.00 |
| Aug 27, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $5.00 |
Clearside Biomedical Inc. (CLSD) Competitors
The following stocks are similar to Clearside based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Clearside Biomedical Inc. (CLSD) Financial Data
Clearside Biomedical Inc. has a market capitalization of $5.76M with a P/E ratio of -0.2x. The company generates $3.33M in trailing twelve-month revenue with a 91.0% profit margin.
Revenue growth is -80.6% quarter-over-quarter, while maintaining an operating margin of -3,502.5% and return on equity of +88.4%.
Valuation Metrics
Market Cap
$5.76M
Enterprise Value
$57.06M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
-80.6%
Gross Margin
+100.0%
Operating Margin
-3,502.5%
Net Margin
+91.0%
EPS Growth
-80.6%
Financial Health
Cash/Price Ratio
+118.1%
Current Ratio
3.0x
Debt/Equity
-1.1x
ROE
+88.4%
ROA
-70.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Clearside Biomedical Inc. (CLSD) Business Model
About Clearside Biomedical Inc.
What They Do
Develops therapies for eye diseases.
Business Model
The company utilizes its proprietary SCS Microinjector technology for targeted drug delivery to the back of the eye. This innovative method enhances treatment effectiveness while minimizing side effects, allowing Clearside Biomedical to monetize its pipeline of therapies for various eye conditions such as macular edema and retinal vein occlusion.
Additional Information
Clearside Biomedical is positioned as a key player in the biopharmaceutical sector, focusing on severe visual impairments and blindness. Their advancements in ocular drug delivery reflect a commitment to improving patient outcomes and compliance, addressing a growing global demand for effective eye disease treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
32
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Country
United States
IPO Year
2016
Website
clearsidebio.comClearside Biomedical Inc. (CLSD) Latest News & Analysis
Latest News
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
1 month ago
Quick Summary
Clearside Biomedical, Inc. has filed for Chapter 11 bankruptcy, despite having a validated delivery platform and ongoing clinical programs for eye diseases.
Why It Matters
Clearside Biomedical's Chapter 11 filing signals financial distress, potentially impacting stock value and investor confidence, while future revenue from collaborations and clinical programs remains uncertain.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Clearside Biomedical (CLSD) reported a quarterly loss of $1.14 per share, worse than the estimated loss of $0.67, compared to a loss of $1.50 per share a year prior.
Why It Matters
CLSD's larger-than-expected quarterly loss signals potential financial instability, raising concerns about its growth prospects and impacting investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Clearside's SCS Microinjector® platform is showcased for its versatility in treating various retinal diseases, indicating potential for expanded market applications.
Why It Matters
Clearside's SCS Microinjector® platform's versatility suggests potential for expanded market opportunities and revenue growth in the retinal disease treatment sector, impacting investor sentiment positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Clearside Biomedical (CLSD) reported a quarterly loss of $0.06 per share, better than the estimated loss of $0.12 and an improvement from a loss of $0.10 per share a year earlier.
Why It Matters
CLSD's smaller-than-expected quarterly loss indicates improved financial performance, potentially boosting investor confidence and impacting stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
5 months ago
Quick Summary
Clearside Biomedical's XIPERE has received approval from Health Canada for treating uveitic macular edema via its SCS injection platform. This marks further global market expansion for the company.
Why It Matters
XIPERE's global approval enhances Clearside Biomedical's market position, potentially increasing revenue streams and boosting investor confidence in its innovative delivery platform.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A new non-surgical procedure for targeted delivery of various therapies for serious retinal diseases has been proven effective in-office and is repeatable.
Why It Matters
Breakthrough procedures for retinal diseases can enhance market potential for related biotech firms, driving stock performance and attracting investment interest in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CLSD Stock
What is Clearside Biomedical Inc.'s (CLSD) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Clearside Biomedical Inc. (CLSD) has a median price target of $60.00. The highest price target is $90.00 and the lowest is $30.00.
Is CLSD stock a good investment in 2026?
According to current analyst ratings, CLSD has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLSD stock?
Wall Street analysts predict CLSD stock could reach $60.00 in the next 12 months. This represents a 5,354.5% increase from the current price of $1.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Clearside Biomedical Inc.'s business model?
The company utilizes its proprietary SCS Microinjector technology for targeted drug delivery to the back of the eye. This innovative method enhances treatment effectiveness while minimizing side effects, allowing Clearside Biomedical to monetize its pipeline of therapies for various eye conditions such as macular edema and retinal vein occlusion.
What is the highest forecasted price for CLSD Clearside Biomedical Inc.?
The highest price target for CLSD is $90.00 from at , which represents a 8,081.8% increase from the current price of $1.10.
What is the lowest forecasted price for CLSD Clearside Biomedical Inc.?
The lowest price target for CLSD is $30.00 from at , which represents a 2,627.3% increase from the current price of $1.10.
What is the overall CLSD consensus from analysts for Clearside Biomedical Inc.?
The overall analyst consensus for CLSD is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $60.00.
How accurate are CLSD stock price projections?
Stock price projections, including those for Clearside Biomedical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 7:55 AM UTC